Clinical Trial

Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The trial consists of Stage 1 (including dose escalation and dose expansion) and Stage 2 (proof-of-concept study). Among them, Stage 2 adopts a randomized, controlled, open-label, and multicenter design.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-25.
Status change: Not Yet Recruiting → Recruiting 2025-09-02
Trial Details
NCT Number NCT06947291
Lead Sponsor CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
Enrollment 350 participants
Start Date 2025-06-04
Primary Completion 2027-04-30 (estimated)
Study Completion 2027-10-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-08